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Abstract
AIM: To study the prevalence, predictors and control 
of bleeding following N-butyl 2 cyanoacrylate (NBC) 
sclerotherapy of gastric varix (GV). 
METHODS: We analyzed case records of 1436 patients 
with portal hypertension, who underwent endoscopy 
during the past five years for variceal screening or 
upper gastrointestinal (GI) bleeding. Fifty patients with 
bleeding GV underwent sclerotherapy with a mean of 
2 mL NBC for control of bleeding. Outcome parameters 
were primary hemostasis (bleeding control within the 
first 48 h), recurrent bleeding (after 48 h of esophago-
gastro-duodenoscopy) and in-hospital mortality were 
analyzed. 
RESULTS: The prevalence of GV in patients with portal 
hypertension was 15% (220/1436) and the incidence of 
bleeding was 22.7% (50/220). Out of the 50 bleeding 
GV patients, isolated gastric varices (IGV-I) were seen in 
22 (44%), gastro-oesophageal varices (GOV) on lesser 
curvature (GOV-Ⅰ) in 16 (32%), and GOV on greater 
curvature (GOV-Ⅱ) in 15 (30%). IGV-Ⅰ was seen in 
44% (22/50) patients who had bleeding as compared 
to 23% (39/170) who did not have bleeding (P  < 
0.003). Primary hemostasis was achieved with NBC in 
all patients. Re-bleeding occurred in 7 (14%) patients 
after 48 h of initial sclerotherapy. Secondary hemostasis 
was achieved with repeat NBC sclerotherapy in 4/7 
(57%). Three patients died after repeat sclerotherapy, 
one during transjugular intrahepatic portosystemic 
stem shunt (TIPSS), one during surgery and one due to 
uncontrolled bleeding. Treatment failure-related mortality 
rate was 6% (3/50).
CONCLUSION: GV can be seen in 15% of patients with 
portal hypertension and the incidence of bleeding is 
22.7%. NBC is highly effective in controlling GV bleeding. 
In hospital mortality of patients with bleeding GV is 6%.
© 2007 The WJG Press. All rights reserved.
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Gastric varix (GV) and its association with portal 
hypertension were first described in 1913[1]. Since then, 
there have been reports on different aspects of  gastric 
varices including prevalence, bleed tendency and treatment 
options. The prevalence of  GV in patients with portal 
hypertension varies from 18% to 70%[2,3], although the 
incidence of  bleeding from gastric varices is relatively low 
ranging from 10% to 36%[3].
Management of  GV presents is a challenging problem, 
because (1) since there is no consensus regarding the 
optimum treatment of  GV, treatment tends to be empiric; 
(2) GV is not a homogeneous entity, and accurate 
classification defines its natural history and dictates its 
management; (3) although GV bleeding occurs less 
frequently than esophageal varix (EV) bleeding[4,5], 
whenever bleeding occurs it tends to be more severe 
and requires more red blood cell transfusions and has a 
higher mortality than EV bleeding[5]; (4) after control of  
acute bleeding, GV has a high rebleeding rate of  34% to 
89%[6]; and (5) there is no consensus regarding subsequent 
sclerotherapy for prophylaxis against recurrent bleeding 
in GV patients. Optimal management of  GV requires a 
multidisciplinary approach and close cooperation between 
gastroenterologists, interventional radiologists and the 
surgical team. 
Sohendra et al[7] first reported in 1986 that bleeding 
from gastric varices could be controlled by sclerotherapy 
www.wjgnet.com
using the tissue adhesive agent butyl cyanoacrylate. 
Since then several authors have used different sclerosing 
agents to achieve hemostasis in bleeding gastric varices, 
including N-butyl-2 cyanoacrylate (histoacryl)[4,8], 2-octyl 
cyanoacrylate[9], ethanolamine oleate injection[10], gastric 
variceal banding[11], thrombin[12], sodium tetradecyl 
sulfate[13]. However, N-butyl 2 cyanoacrylate (NBC) is the 
only promising agent. 
Most reports on endoscopic treatment of  bleeding 
gastric varices are small series, case reports, or retrospective 
reviews[14,15]. Not more than 1000 patients with bleeding 
GV have been treated with different sclerosing and 
coagulating agents. Cyanoacrylate injection can achieve 
primary hemostasis in 70% to 95% of  patients with 
acute GV bleeding, with an early rebleeding rate ranging 
from 0% to 28% within 48 h[5,7,16]. Different doses of  
cyanoacrylate are used by different gastroenterologis
ts[16,17]. Moreover, dilution ratio of  NBC to lipoidal is 
different[18,19]. However, there is no consensus regarding 
effective dose and dilution of  sclerosing agents.
This study was to analyze patients with GV in order to 
establish predictors of  bleeding GV, and the efficacy and 
safety of  NBC in treatment of  bleeding GV. 
MATERIALS AND METHODS
From March 2000 to March 2005, 1036 patients with 
portal hypertension underwent endoscopy in our hospital. 
Out of  220 GV patients with or without esophageal 
varices, 50 had active bleeding gastric varices which were 
treated with N-Butyl cyanoacrylate injection.  
The cause of  portal hypertension was defined on the 
basis of  ultrasound and/or computed tomographic scan 
of  abdomen along with Doppler ultrasound to study the 
patency and spleno-portal axis in all patients with bleeding 
GV.
The location of  gastric varices was determined 
according to the classification described by Sarin and 
Kumar[3] and divided into gastroesophageal varices type 
1 (GOV-1) GV continuing as an extension of  esophageal 
varices on the lesser curve of  the stomach), gastro-
esophageal varices type 2 (GOV-2) on the greater curvature 
or fundal varices communicating with esophageal varices. 
Isolated gastric varices type 1 (IGV-1) and fundal varices 
within a few centimeters of  the gastric cardia, or isolated 
gastric varices type 2 (IGV-2) and isolated ectopic gastric 
varices. Active bleeding was defined as bleeding or oozing 
of  blood from a gastric varix, a clot or blackish ulcer or 
rent over a gastric varix, or the presence of  distinct large 
gastric varices and absence of  esophageal varices or other 
cause of  gastrointestinal (GI) bleeding.
The clinical characteristics of  patients including age, 
gender, Child-Pugh classification, type of  varix, etiology 
and complications in patient with gastric varices were 
recorded and compared between groups with or without 
bleeding (Table 1).
Endoscopic sclerotherapy with n-butyl cyanoacrylate 
and lipoidal injection was performed by experienced 
endoscopists using a GIFQ160 gastroscope (Olympus, 
Tokyo, Japan). The sclerosant was injected into bleeding 
gastric varices using the 23 G disposable needle injector 
(Wilson Cook Medical Inc., Winston-Salem, NC). 
The inject ion needle was primed with l ipoidal 
(approximately 0.5 mL) to fill the dead space within 
the injection catheter. After the gastric varix lumen was 
punctured with the needle, 2 mL of  NBC (histoacryl 
100%) in aliquots of  1 mL, diluted in 0.5 mL lipoidal, was 
injected over 45-90 s, thus a dilution of  2:1 was achieved in 
all cases (Figure 1 and Figure 2). Distilled water was used 
to flush the injection needle before and after sclerotherapy. 
Additional NBC was not injected if  bleeding was 
immediately controlled in patients. All patients received 
octreotide infusion (50 mg/per hour) at admission and 
continued for 3 d. All patients were given a proton pump 
inhibitor, initially intravenously for 48 h and then orally for 
4-6 wk as per our endoscopy unit protocol. 
Outcome measures
Primary hemostasis was defined as stability of  vital 
clinical signs, no drop in hemoglobin concentration and 
no recurrent bleeding within the first 48 h after the initial 
sclerotherapy[16]. Re-bleeding was defined as hematemesis 
and/or melena, hypotension (a drop in systolic blood 
pressure of  > 20 mmHg from baseline), fall in 2 gm/dL 
of  hemoglobin and/or transfusion requirement of  ≥ 2 
units of  packed red cells within that time.
Data analysis
Statistical interpretation of  data was performed using 
Statistical Program for Social Sciences (SPSS) version 13. 
Results were expressed as mean ± SD for all continuous 
variables (e.g., age, gender, hospital stay, units of  packed 
cells etc.) and numbers (percentage) for categorical data 
(e.g., gender, Child’s class, etc.). Analysis was performed by 
using the independent t-test, chi-square test and Fisher’s 
exact test wherever appropriate. P < 0.05 was considered 
statistically significant. 
Table 1  Clinical characteristics of patients with gastric varices
Characteristics n (%)
Number of patients 220
Male:Female 141:79 (65:35)
Mean age (yr) 50 ± 11
Etiology of GV
    HCV cirrhosis 155 (70)
    HBV cirrhosis   38 (17.5)
    NBNC   27 (12.5)
    NCPHTN     9
    Alcoholism     5
    Budd-Chiari syndrome     1
    Wilson’s disease     1
Child-Pugh classification
(A/B/C) 39/109/72 (18/49/33)
Types of gastric varices
    GOV-1 78 (35)
    GOV-2 56 (25)
    IGV-1 59 (27)
    IGV-2   6 (03)
    GOV-1 + GOV-2 14 (06)
    GOV-2 + IGV-2   3 (1.5)
    GOV 1+IGV 2   2 (01)
    GOV 1 + IGV 1   2 (01)
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RESULTS
The prevalence of  bleeding gastric varices in patients 
with portal hypertension was 15% (220/1436) and the 
incidence of  bleeding was 22.7% (50/220). The mean age 
of  our patients with gastric varices was 50 ± 11 years, male 
patients accounting for 65% (141). The main etiology of  
bleeding gastric varices was hepatitis C-related cirrhosis in 
34 (68%), followed by hepatitis B virus in 6 and non B non 
C cirrhosis in 6 (12%) patients, respectively. Alcoholic liver 
disease was found in 2 patients (4%), non cirrhotic portal 
hypertension in 1 patient and Wilson’s disease in 1 patient, 
respectively. Twelve patients (24%) belonged to Child-
Pugh A, 26 (52%) to Child-Pugh B, and 12 (24%) to Child-
Pugh C. 
Out of  the 50 bleeding GV patients, IGV-Ⅰwas seen 
in 22 patients (44%), GOV-Ⅰin 16 patients (32%), and 
GOV-Ⅱ in 15 patients (30%), concomitant GOV-Ⅰwith 
GOV-Ⅱ in 3 patients. N-butyl cyanoacrylate (2 mL diluted 
in 1 cc lipoidal) was injected intravariceally in all patients 
with bleeding GV. The characteristics of  bleeding and non 
bleeding gastric varices are shown in Table 2. 
Among these 50 patients, 43 (86%) had active bleeding 
and 7 (14%) showed evidence of  recent bleeding. Most 
varices (n = 48) were large (F3) according to Hashizume 
classification[20]. We compared bleeding and non bleeding 
GV and found that IGV-Ⅰwas seen in 22/50 (44%) 
patients who had bleeding and in 39/170 patients (23%) 
patients who did not have bleeding (P < 0.003). Similarly, 
IGV-Ⅱ was observed in 0/50 (0%) and 11/170 (6.4%), 
GOV-Ⅰin 16/50 (32%) and 77/170 patients (45.2%) 
who did not have bleeding, GOV-Ⅱ in 15/50 (30%) and 
50/170 patients (29.4%) who did not have bleeding from 
gastric varices, respectively. 
The overal l success rate for achieving primary 
hemostasis with NBC was 100% without recurrent 
bleeding within 48 h. A mean of  2.0 ± 0.5 cc NBC was 
injected in each patient. 
Re-bleeding occurred in 7 (14%) patients after 48 h. 
Secondary hemostasis with repeat NBC sclerotherapy was 
achieved in 4 (57%) patients. Three patients died after 
repeat sclerotherapy: one during transjugular intrahepatic 
portosystemic stem shunt (TIPSS), one during surgery and 
one due to uncontrollable torrential bleeding. Treatment 
failure-related mortality rate was 6 % (3/50).
No major side effects occurred in most patients during 
and after NBC sclerotherapy. Three patients reported mild 
retrosternal chest pain which subsided within the next 24 h 
(Figure 3).
Figure 1  Isolated gastric varices with a nipple suggesting recent bleeding. Figure 2  Injector needle with N- butyl cyanoacrylate in a large gastric fundal varix.
Table 2  Comparison between bleeding and non bleeding varices
Characteristics Bleeding GV 
    n (%)
Non bleeding GV 
       n (%)
P
Age 50.48 ± 11.2   47.52 ± 12.7 0.14
Gender
    Male 30 (60) 111 (65.3)
    Female 20 (40)   59 (34.7) 0.49
Child Pugh class.
    A 12 (24)   27 (15.9)
    B 26 (52)   83 (48.8) 0.22
    C 12 (24)   60 (35.3)
Type of GV
    GOV-Ⅰ 16 (32)   77 (45.3) 0.09
    GOV-Ⅱ 15 (30)   58 (34.1) 0.58
    IGV-Ⅰ 22 (44)   39 (22.9) < 0.01
    IGV-II   0 (0)   11 (6.5) 0.06
Etiology of PHTN
    HBV   6 (12)   29 (17.1) 0.39
    HCV 34 (68) 121 (71.2) 0.76
    NBNC   6 (12)   21 (12.4) 0.94
    Alcoholic 02 (2)   03 (1.8) 0.48
    Non cirrhotic PHTN 01 (2)   08 (4.7) 0.59
    Wilson’s disease 01 (2)   00 (0) 0.06
Figure 3  X-ray showing N-butylcyanoacrylate deposition in a gastric varix after 
sclerotherapy.
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DISCUSSION
The overall incidence of  gastric varices in patients with 
portal hypertension is 2%-70%[3]. Furthermore, we found 
that the incidence of  bleeding from gastric varices in our 
patients is 22.7%, which is also similar to other reports[5].
In this study, the rate for primary hemostasis with NBC 
injection is consistent with the reported rate of  90% to 
97% in other studies[8,14,16,21-23]. In our study, sclerotherapy 
with 2 mL NBC diluted in 1 mL lipoidal was effective in 
control of  bleeding in all our patients during the first 48 h. 
We used a higher dose of  NBC with 2:1 dilution. 
Our technique avoids dilution of  NBC, thus decreasing 
chances of  migration and embolization as instantaneous 
polymerization is delayed. 
It was reported that a hemostasis rate of  95% can be 
achieved without dilution of  NBC, but serious side effects 
such as embolization may occur[24]. 
The risk of  embolization increases with over dilution 
of  cyanoacrylate which can slow down the process of  
polymerization. We avoided this problem by diluting 2 mL 
of  NBC in 1 mL of  lipoidal which was injected slowly 
over 45-90 s. Although the volume of  injection was large, 
the side effects of  a large volume were avoided and good 
hemostais was achieved by keeping a balanced dilution.
We also studied the predictors of  the first gastric 
variceal bleeding, showing that the increased risk of  
bleeding is associated with larger varices including 
predominant IGV-Ⅰand GOV-Ⅰ[5]. Kim et al[23] found 
that advanced Child-Pugh class and varix > 5 mm in size 
are associated with an increased risk of  bleeding. Unlike 
esophageal varices, a high porto-systemic pressure > 12 
mmHg does not cause GV bleeding, which is probably 
related to the high frequency of  spontaneous gastro-renal 
shunts[17]. 
Cyanoacrylate therapy can improve and control re-
bleeding. The high mortality rate is primarily a reflection 
of  underlying advanced liver disease unaffected by the 
injection of  cyanoacrylate[25,26]. This is further explained by 
a study of  Kim et al[23] in which they prospectively followed 
a cohort of  patients with gastric varices who did not 
undergo endoscopic therapy and found that the mortality 
rate is 35% over a median of  15 mo. Therefore, the role 
and efficacy of  sclerotherapy for prophylaxis against 
recurrent bleeding are questionable. 
In the present study, re-bleeding occurred after 48 h 
in 7 (14%) patients and was controllable in 4 (57%) with 
repeat injection of  NBC. It was reported that the incidence 
of  re-bleeding ranges from 23% to 35%[8,10,16]. However, 
Kind et al[14] reported that the incidence of  re-bleeding is 
15.5%.
Treatment failure-related mortality in our study was 
6%, which is consistent with the reported mortality[16]. 
Another study showed that the mortality is 12.5% due to 
re-bleeding immediately after NBC sclerotherapy[8]. Kind 
et al[14] reported that the hospital mortality rate is 19.5% in 
patients with bleeding gastric varices.
In conclusion, endoscopic injection of  NBC at a 
dilution of  2:1 appears to be effective and safe for the 
control of  hemostasis in patients with bleeding gastric 
varices. If  NBC is injected slowly, a large amount of  
NBC in proper dilution can be used without serious side 
effects.
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